A Phase 1/2 interventional study of acalabrutinib and vistusertib in DLBCL and Richter Syndrome, sponsored by Acerta Pharma BV. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
First submitted after Acerta Pharma BV became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):
Prior treatment for lymphoid :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
acalabrutinib daily + vistusertib daily
Drug: acalabrutinib · Drug: vistusertib
acalabrutinib daily + vistusertib 5 days on and 2 days off
Drug: acalabrutinib · Drug: vistusertib
Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
Also known as: ACP-196
Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
Also known as: AZD2014
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).
Time frame: From first dose of study drug until 30 days post last dose
| Milestone | Acalabrutinib 100 mg BID Plus Vistusertib BID Continuous | Acalabrutinib 100 mg BID Plus Vistusertib BID Intermittent |
|---|---|---|
| Started | 13 | 12 |
| Completed | 0 | 2 |
| Not completed | 13 | 10 |
| Withdrew: Death | 10 | 6 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 1 |
Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).
| Participants | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 13 | 12 |
Collected over Serious Adverse Events and Other Adverse Events were assessed from first dose of study drug until 30 days post last dose; All-Cause Mortality was assessed from first dose of study drug until death, loss to follow up, sponsor decision to stop trial, or withdrawal of consent, whichever occurred first, an average of approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | 10/13 (76.9%) | 2/13 (15.4%) | 13/13 (100%) |
| Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | 6/12 (50%) | 6/12 (50%) | 12/12 (100%) |
| Event | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/13 | 2/12 |
| PneumoniaInfections and infestations | 0/13 | 2/12 |
| Lymph node painBlood and lymphatic system disorders | 0/13 | 1/12 |
| AstheniaGeneral disorders | 0/13 | 1/12 |
| PyrexiaGeneral disorders | 1/13 | 1/12 |
| Lower respiratory tract infectionInfections and infestations | 0/13 | 1/12 |
| Computerised tomogram thorax abnormalInvestigations | 0/13 | 1/12 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/13 | 1/12 |
| SyncopeNervous system disorders | 0/13 | 1/12 |
| Trigeminal neuralgiaNervous system disorders | 0/13 | 1/12 |
| Event | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent |
|---|---|---|
| NauseaGastrointestinal disorders | 1/13 | 8/12 |
| FatigueGeneral disorders | 4/13 | 8/12 |
| Blood creatinine increasedInvestigations | 4/13 | 7/12 |
| ConstipationGastrointestinal disorders | 0/13 | 6/12 |
| Decreased appetiteMetabolism and nutrition disorders | 0/13 | 6/12 |
| DiarrhoeaGastrointestinal disorders | 6/13 | 2/12 |
| AnaemiaBlood and lymphatic system disorders | 2/13 | 5/12 |
| VomitingGastrointestinal disorders | 1/13 | 5/12 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/13 | 5/12 |
| HypotensionVascular disorders | 0/13 | 5/12 |
| Age, Continuous(Years) | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | Total |
|---|---|---|---|
| Mean | 63.6 ± 15.9 | 67.3 ± 12.0 | 65.4 ± 13.99 |
| Sex: Female, Male(Participants) | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | Total |
|---|---|---|---|
| Female | 4 | 2 | 6 |
| Male | 9 | 10 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 11 | 11 | 22 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 12 | 11 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous | Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent | Total |
|---|---|---|---|
| United States | 5 | 9 | 14 |
| United Kingdom | 8 | 3 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2017 to primary completion in Nov 2019, 28 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acalabrutinib · Vistusertib